MCRB News and Press, Seres Therapeutics Inc.

2026-03-03 11:12:18 ET Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform March 3, 2026 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Seres Therapeutics, Inc. (MCRB) Discu...

2026-03-02 16:24:02 ET More on Seres Therapeutics Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' Seres down after pausing investments for lead program Seeking Alpha’s Quant Rating on Seres Therapeutics Historical earni...

Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-15...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 7.7% to $1.81 on volume of 859,097,032 shares Signing Day Sports Inc. (SGN) rose 29.1% to $0.2735 on volume of 412,488,200 shares ChowChow Cloud International Holdings Limited (CHO...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 7.7% to $1.81 on volume of 795,239,382 shares Signing Day Sports Inc. (SGN) rose 43.8% to $0.3047 on volume of 391,108,986 shares ChowChow Cloud International Holdings Limited (CHO...

2026-02-12 09:12:07 ET More on Seres Therapeutics Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' Seeking Alpha’s Quant Rating on Seres Therapeutics Historical earnings data for Seres Therapeutics Financial information ...

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoi...

2026-02-06 18:28:50 ET ... Read the full article on Seeking Alpha For further details see: Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'

Data demonstrate  clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx ® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres’ portfol...

2025-11-05 14:12:11 ET More on Seres Therapeutics Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more See...